AAV Vector Stuffer Sequences for Residual DNA Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing recombinant adeno-associated virus (AAV) vectors face challenges in removing DNA impurities, particularly wild-type/pseudo wild-type AAV species and AAV-encapsidated residual DNA, which are difficult to separate during purification due to their resemblance to the vector and resistance to nuclease treatment.
Innovation Solution
Incorporation of inert filler or stuffer polynucleotide sequences within the AAV vector plasmid, positioned outside or within AAV ITR sequences, to optimize vector genome size and minimize encapsidation of impurities, thereby reducing residual DNA levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If nuclease treatment is performed to remove accessible nucleic acids during vector purification, then DNA impurities are reduced, but fragments of DNA may be packaged and thus resistant to nuclease treatment
Solution Approach 1:
The patent incorporates filler/stuffer sequences into the vector plasmid design before purification. These sequences occupy packaging capacity in advance, preventing residual DNA from being packaged into viral particles. This preliminary structural modification ensures that even if nuclease treatment is insufficient, the packaged DNA will be inert filler rather than harmful residual sequences.
Solution Approach 2:
The invention extracts the problematic residual DNA sequences from the vector plasmid by replacing them with inert filler/stuffer sequences in the backbone region. This separation allows the essential vector functions to be maintained while the harmful packaging of residual DNA is eliminated through the use of non-packagable filler sequences.
2Productivity
If the vector genome size is optimized to accommodate heterologous polynucleotide sequences, then packaging efficiency is improved, but DNA impurities may be co-packaged
Solution Approach 1:
The patent applies local quality by creating distinct functional regions within the plasmid: the vector genome region (within ITRs) contains essential packaging signals and heterologous sequences, while the backbone region contains inert filler sequences. This spatial differentiation ensures that only the desired vector genome is packaged, while the filler occupies excess capacity without being packaged, thereby improving both packaging efficiency and purity.
Solution Approach 2:
The filler/stuffer sequences act as an intermediary element that occupies the space between the essential vector genome and the harmful residual DNA. This intermediary occupies packaging capacity and prevents residual DNA from being incorporated, thereby mediating between the need for efficient packaging and the need for high purity.
3Manufacturing precision
If inert filler polynucleotide sequences are incorporated to minimize encapsidation of impurities, then vector purity is enhanced, but plasmid complexity increases
Solution Approach 1:
The patent changes the compositional parameters of the plasmid by adding filler sequences with specific length ranges (500-10,000 nucleotides) and specific properties (inert, non-packagable). This parameter modification increases plasmid size but dramatically improves vector purity by preventing residual DNA packaging, representing an acceptable trade-off where the complexity increase is offset by the significant purity improvement.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
Recombinant viral vectors such as AAV vectors designed with expression cassettes that approach the natural packaging capacity of the virus, such as AAV are provided. The recombinant viral vectors reduce residual plasmid DNA impurities.